RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials
- 263 Downloads
To conduct a systematic review and meta-analysis of published randomised controlled trials on the efficacy of NAC supplementation on positive and negative syndrome scale in schizophrenia.
A meta-analysis was conducted, and studies were identified by a search of electronic databases from inception to May 2018. Combined and stratified analyses were used.
Seven trials were identified, and data from n = 447 participants were included. Pooled analysis showed improvement of positive and negative syndrome scale following NAC treatment compared with placebo, for total (SMB = − 0.96) [95% CI − 1.69, − 0.24; P = 0.009], general (SMB = − 1.04) [95% CI − 1.80, − 0.27; P = 0.008] and negative (SMB = − 0.73) [95% CI − 1.29, − 0.17; P = 0.01] scores, respectively. Significant heterogeneity was found, and subgroup analysis showed significant reductions in studies with a treatment duration of ≤ 24 weeks, with a considerable effect size on total, general, and negative scores (Total SMD = − 0.83; General SMD = − 0.67; Negative SMD = − 1.09) following NAC.
NAC improved all aspects of positive and negative syndrome scale in schizophrenic populations and may be more efficacious with treatment durations up to 24 weeks.
KeywordsN-acetyl cysteine Schizophrenia PANSS Meta-analysis
- 5.Rossell SL, Francis PS, Galletly C, Harris A, Siskind D, Berk M, Bozaoglu K, Dark F, Dean O, Liu D, Meyer D, Neill E, Phillipou A, Sarris J, Castle DJ (2016) N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. BMC Psychiatry 16(1):320CrossRefGoogle Scholar
- 9.Pavlović D et al (2002) Oxidative stress as marker of positive symptoms in schizophrenia. Facta Univ 9:157–161Google Scholar
- 13.Lewis R (2004) Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiatry Neurosci 29(2):102–113Google Scholar
- 15.Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, der Heiden WA, Holmberg SK, Janca A, Lee PWH, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178:506–517CrossRefGoogle Scholar
- 23.Otte DM, Sommersberg B, Kudin A, Guerrero C, Albayram Ö, Filiou MD, Frisch P, Yilmaz Ö, Drews E, Turck CW, Bilkei-Gorzó A, Kunz WS, Beck H, Zimmer A (2011) N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology 36(11):2233–2243CrossRefGoogle Scholar
- 28.Sansone RA, Sansone LA (2011) Getting a knack for NAC: N-acetyl-cysteine. Innov Clin Neurosci 8(1):10–14Google Scholar
- 31.Association AP (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric PubGoogle Scholar
- 35.Jafarnejad S, Keshavarz SA, Mahbubi S, Saremi S, Arab A, Abbasi S, Djafarian K (2017) Effect of ginger (Zingiber officinale) on blood glucose and lipid concentrations in diabetic and hyperlipidemic subjects: a meta-analysis of randomized controlled trials. J Funct Foods 29:127–134CrossRefGoogle Scholar
- 36.Hosseini B et al (2018) The effect of omega-3 fatty acids, EPA, and/or DHA on male infertility: a systematic review and meta-analysis. J Dietary Suppl:1–12Google Scholar
- 40.Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y, Francis MM (2018) Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res 199:395–402CrossRefGoogle Scholar
- 41.Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64(5):361–368CrossRefGoogle Scholar
- 42.Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SMR, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SMH, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S (2013) N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 36(6):185–192CrossRefGoogle Scholar
- 45.Magalhães PV et al (2016) Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev 2Google Scholar
- 49.Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R, Ng F, Copolov DL, Bush AI (2011) Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. J Clin Psychiatry 72:909–913CrossRefGoogle Scholar
- 53.Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SMR, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S (2014) A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology 231(3):533–542CrossRefGoogle Scholar